Elevation Oncology launches with $32.5 million Series A, gives new life to former Merrimack program
Almost two years ago, Merrimack’s high-profile seribantumab program flopped in a trial that attempted to treat non-small cell lung cancer in combination with another drug. Now, that program is getting a second chance.
Elevation Oncology announced its launch Tuesday with $32.5 million in Series A funding and seribantumab as its lead candidate. Rather than focusing on NSCLCs like Merrimack, Elevation will aim to use the compound to treat solid tumors with the rare NRG1 genomic fusion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.